PPMX-T002 is under clinical development by Perseus Proteomics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PPMX-T002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PPMX-T002 (FF-21101) is under development for the treatment of solid tumors including pancreatic neuroendocrine tumor, ovarian cancer, liposarcoma, vaginal cancer, desmoplastic small round cell (DSRC) tumor epithelial ovarian cancer, peritoneal cancer, fallopian tube carcinoma, metastatic biliary tract cancer, triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), cholangiocarcinoma, pancreatic carcinoma and colorectal cancer. The drug is administered by injection. It is a radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90.
It was also under development for the treatment of oral cavity (mouth) cancer, papillary tumor, maxillary sinusitis, oropharyngeal cancer, hypopharyngeal cancer, non-small cell lung cancer, islet cell carcinoma and laryngeal cancer.
For a complete picture of PPMX-T002’s drug-specific PTSR and LoA scores, buy the report here.